Genmab — December 2012
-
det kan sku godt blive en god forretning
-
det kan blive en patentforlænger?
-
ja det kan det
-
jeg elsker når han siger No risk
-
det var på Daratumumab
-
så er der keymilestones
-
A year of data & deals
-
Yes sir
-
operating loss will være lavere end i 2012
-
reduce cashburn
-
jeg tager den nedefra
-
flere aftale, flere partnerskaber
-
guidance kommer tidlig marts 2013
-
q1
-
det kunne godt se ud som om at taburetten blev til en stol
-
måske endda med 5 ben
-
david kommer nu
-
kør nu finance spørgsmål
-
Samir
-
Hexabody
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind